Convention Name Individuals
Alexandria Hammond – Wolfe Analysis, LLC
Terence Flynn – Morgan Stanley, Analysis Division
David Risinger – Leerink Companions LLC, Analysis Division
Evan Seigerman – BMO Capital Markets Fairness Analysis
Louise Chen – Scotiabank World Banking and Markets, Analysis Division
Geoffrey Meacham – Citigroup Inc., Analysis Division
Jason Gerberry – BofA Securities, Analysis Division
Mohit Bansal – Wells Fargo Securities, LLC, Analysis Division
Christopher Schott – JPMorgan Chase & Co, Analysis Division
Courtney Breen – Sanford C. Bernstein & Co., LLC., Analysis Division
Carter Gould – Cantor Fitzgerald & Co., Analysis Division
Kerry Holford – Joh. Berenberg, Gossler & Co. KG, Analysis Division
Vamil Divan – Guggenheim Securities, LLC, Analysis Division
Christopher LoBianco – TD Cowen, Analysis Division
Asad Haider – Goldman Sachs Group, Inc., Analysis Division
Presentation
Operator
A great day, everybody, and welcome to Pfizer’s analyst and investor name to evaluate the total yr 2026 monetary steering. Right this moment’s name is being recorded. Presently I want to flip the decision over to Francesca DeMartino, chief investor relations officer and senior vp. Please go forward, ma’am.
Francesca DeMartino
Chief Investor Relations Officer
Good morning, and welcome to Pfizer’s 2026 monetary steering name. I am Francesca DeMartino, chief investor relations officer. On behalf of the Pfizer group, thanks for becoming a member of us. This name is being made obtainable through audio webcast at Pfizer.com. Earlier this morning we launched our 2026 monetary steering through a press launch that’s obtainable at our web site, Pfizer.com. I am doing immediately by Dr. Albert Bourla, our Chairman and CEO, and Dave Denton, our CEO. Albert and Dave have ready remarks after which we’ll open the decision for questions. Earlier than you get began I need to remind you that we’ll be making forward-looking
